MIR:CA:CDX-MedMira Inc. (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 0.085

Change

+0.01 (+6.25)%

Market Cap

USD 0.02B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

MedMira Inc is a biotechnology company. The Company through its subsidiaries, is engaged in research, development and manufacturing of rapid diagnostics and technologies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.16B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.03B
CZO:CA Ceapro

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

N/A

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing MIR:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.73% 19% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.73% 19% F 27% F
Trailing 12 Months  
Capital Gain -34.62% 43% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.62% 43% F 48% F
Trailing 5 Years  
Capital Gain 750.00% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 750.00% 100% F 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 693.30% 100% F 99% N/A
Dividend Return 693.30% 100% F 99% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,668.05% 4% F 1% F
Risk Adjusted Return 41.56% 88% B+ 85% B
Market Capitalization 0.02B 92% A 89% A-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector